India vs Vietnam for Pharma Manufacturing: Cost, Talent & Regulatory Comparison

The Pharma Manufacturing Landscape: India's Dominance vs Vietnam's Emergence

India and Vietnam occupy fundamentally different positions in the global pharmaceutical manufacturing value chain. India is the world's third-largest producer of active pharmaceutical ingredients (APIs), accounting for 8% of the global API industry, and supplies 20% of global generic drug volume. Vietnam, meanwhile, is an emerging market with significant growth potential but limited current manufacturing capabilities.

For foreign pharmaceutical companies evaluating manufacturing locations in Asia, the choice between India and Vietnam depends on product type (API vs formulation), target markets (regulated vs emerging), required certifications (US-FDA, EU-GMP, WHO-GMP), and investment scale. This comparison provides the data needed for an informed decision in 2026.

API and Bulk Drug Manufacturing: India's Commanding Lead

India's API Manufacturing Ecosystem

India manufactures over 500 different APIs and contributes 57% of APIs to the WHO prequalified list. The country has transitioned from a net importer of bulk drugs (INR 1,930 crore deficit in FY 2021-22) to a net exporter (INR 2,280 crore surplus in FY 2024-25), driven by the PLI scheme for bulk drugs.

Key API manufacturing facts for 2026:

• Market size: India's API market is valued at approximately $15.28 billion in 2026
• Critical APIs: 38 previously-imported APIs now manufactured domestically under PLI, including Penicillin G, Clavulanic Acid, Atorvastatin, and Metformin
• Bulk drug parks: Three government-backed parks in Gujarat, Himachal Pradesh, and Andhra Pradesh providing shared utilities including solvent recovery, effluent treatment, and common infrastructure. The Himachal Pradesh park alone is expected to attract $1.35 billion in investment
• Cost advantage: Setting up and operating a modern pharma plant in India costs approximately 40% less than in Western countries

Vietnam's Pharmaceutical Manufacturing Status

Vietnam's pharmaceutical market is projected to exceed $10 billion by 2026, but its manufacturing base is primarily focused on finished dosage forms rather than API production. Vietnam lacks the industrial chemical base required for large-scale API synthesis.

Key Vietnam pharma facts for 2026:

• Market size: Projected at $10–16 billion by 2026, depending on the source
• FDI in pharma: Only $1.8 billion in cumulative pharmaceutical FDI, indicating massive untapped potential
• Manufacturing focus: Primarily generics formulation and packaging, limited API production
• Import dependence: Vietnam imports the majority of its APIs, primarily from China and India

Regulatory Certifications and Quality Infrastructure

India's Regulatory Ecosystem

India has one of the most mature pharmaceutical regulatory ecosystems in the developing world. The Central Drugs Standard Control Organisation (CDSCO) serves as the national regulatory authority, and Indian manufacturers hold certifications from virtually every major global regulator:

• US-FDA approved plants: India has the highest number of US-FDA approved pharmaceutical manufacturing facilities outside the United States, with over 800 plants registered with the FDA
• EU-GMP certified plants: Hundreds of Indian facilities hold European Medicines Agency (EMA) certification
• WHO-GMP certification: India leads globally in WHO-GMP certified plants, with CDSCO transitioning to fully digital certification via the ONDLS portal from July 2025
• Certificate of Pharmaceutical Product (COPP): Issued digitally through the SUGAM portal, valid for 2 years

This certification infrastructure means products manufactured in India can be exported to regulated markets worldwide without additional qualification hurdles — a decisive advantage for multinational pharma companies.

Vietnam's Regulatory Framework

Vietnam's pharmaceutical regulatory framework has undergone significant reform. The amended Law on Pharmacy (Law No. 44/2024/QH15), effective July 2025, represents a landmark change:

• Foreign investors now receive the same treatment and procedures as domestic firms in manufacturing and export
• Foreign companies can engage in manufacturing, quality control, clinical trials, and self-distribution for products produced via technology transfer
• Circular 40/2025/TT-BYT gives competitive advantages to locally produced, EU-GMP certified drugs in hospital tenders

However, Vietnam's regulatory ecosystem is still developing. The number of internationally certified plants is significantly lower than India's, and the regulatory pathway for complex biologics and novel drugs is less established.

Cost Structure: Manufacturing Economics Compared

Production Costs

India's cost advantage in pharma manufacturing is not just about labor. The three government-backed bulk drug parks provide shared utilities — solvent recovery units, effluent treatment plants, quality testing labs, and common warehousing — that significantly reduce per-company operating costs. This shared infrastructure model is not available in Vietnam.

The Section 115BAB 15% (effective 17.16%) rate applied only to new manufacturers that commenced production by 31 March 2024; that window has closed and was not extended. New pharmaceutical manufacturing companies in India today opt for Section 115BAA, paying an effective corporate tax of approximately 25.17% (22% base plus surcharge and cess), compared to Vietnam's standard 20%. Vietnam offers a preferential 10% rate for high-tech pharmaceutical projects, but this requires additional approvals and is subject to the OECD Pillar Two global minimum tax for large multinationals.

Talent Pool: India's Decisive Advantage in Pharma

Pharmaceutical manufacturing requires specialized talent across multiple functions: process chemistry, analytical chemistry, quality assurance/quality control (QA/QC), regulatory affairs, pharmacovigilance, and GMP-compliant operations. India has a commanding advantage in every category.

India's Pharma Talent Pipeline

• Pharmacy graduates: India produces over 200,000 pharmacy graduates annually from approximately 2,000 pharmacy colleges
• Chemistry PhDs: Over 10,000 doctoral-level chemists graduate annually, many with API synthesis experience
• Experienced workforce: India's pharmaceutical industry employs over 3 million people, creating a deep bench of experienced professionals familiar with US-FDA, EU-GMP, and WHO-GMP requirements
• English proficiency: Regulatory documentation, SOPs, and batch records in Indian plants are universally maintained in English, simplifying integration with global pharma companies

Vietnam's Pharma Talent Situation

Vietnam has approximately 30,000–40,000 workers in pharmaceutical manufacturing. The country produces about 10,000 pharmacy graduates annually, but most are oriented toward retail pharmacy and hospital settings rather than manufacturing. Vietnam faces significant gaps in:

• Process chemistry and API synthesis expertise
• US-FDA and EU-GMP regulatory affairs specialists
• Quality assurance professionals with international audit experience
• Pharmacovigilance and drug safety monitoring professionals

For companies considering complex pharmaceutical manufacturing — particularly API synthesis, biologics, or products requiring US-FDA approval — India's talent advantage is decisive and will remain so for at least the next decade.

Contract Research and Manufacturing (CRDMO) Capabilities

A key differentiator in the pharmaceutical manufacturing landscape is the availability of contract research, development, and manufacturing organizations (CRDMOs). India has emerged as a global hub for pharmaceutical outsourcing, with established players like Dr. Reddy's, Syngene International, Laurus Labs, Aragen Life Sciences, and Piramal Pharma Solutions offering end-to-end services from molecule discovery through commercial manufacturing.

India's CRDMO Advantage

India's CRDMO sector is valued at approximately $20 billion and growing at 12-15% annually. The sector benefits from:

• Chemistry expertise: Indian CRDMO chemists have deep expertise in complex synthetic chemistry, including chiral chemistry, asymmetric synthesis, and continuous flow chemistry — capabilities essential for manufacturing high-potency APIs
• Regulatory track record: Major Indian CRDMOs have passed hundreds of regulatory inspections by the US-FDA, EMA, PMDA (Japan), and TGA (Australia) without critical observations
• Cost advantage: Contract manufacturing costs in India are 30-50% lower than in the US or EU, with comparable quality outputs
• IP protection: India's adherence to TRIPS and an improving patent enforcement environment have made global pharma companies more comfortable with outsourcing sensitive projects to Indian CRDMOs

Vietnam's Contract Manufacturing Status

Vietnam's contract pharmaceutical manufacturing sector is nascent. While the amended Law on Pharmacy (2025) permits technology transfer arrangements, the number of facilities capable of handling complex contract manufacturing projects for regulated markets is extremely limited. Most contract manufacturing in Vietnam is focused on finished dosage forms for the domestic market rather than export-quality API or advanced formulation work.

For multinational pharmaceutical companies seeking to establish contract manufacturing partnerships in Asia, India offers a mature ecosystem with proven capabilities, while Vietnam remains an opportunity for basic formulations targeting ASEAN distribution.

Supply Chain and Raw Material Considerations

Pharmaceutical manufacturing requires reliable access to key starting materials (KSMs), drug intermediates, solvents, and excipients. India's chemical industry — one of the world's largest — provides a domestic supply base for many of these inputs. However, India still imports approximately 68% of its KSMs from China, a dependency the PLI scheme for bulk drugs is designed to address.

Vietnam faces a more challenging raw material situation. The country lacks a significant industrial chemical base and imports virtually all KSMs, drug intermediates, and many excipients. This creates supply chain vulnerability and higher input costs, particularly during global supply disruptions. India's three bulk drug parks are specifically designed to mitigate this risk by creating domestic KSM manufacturing clusters with shared waste treatment and utility infrastructure.

For pharmaceutical manufacturers prioritizing supply chain resilience, India offers a more diversified and self-sufficient raw material ecosystem, while Vietnam remains dependent on imports for most pharmaceutical inputs.

Environmental and Effluent Management

Pharmaceutical manufacturing generates significant volumes of chemical waste and solvent residues requiring specialized treatment. India's bulk drug parks address this challenge through centralized common effluent treatment plants (CETPs) and solvent recovery units shared among multiple manufacturers, reducing individual company compliance costs by an estimated 30-40%. Companies operating outside these parks must establish their own treatment facilities, which adds INR 10-50 crore in capital expenditure depending on production scale.

Vietnam requires individual companies to meet effluent discharge standards, with factory-level wastewater treatment mandatory before discharge. While industrial zones provide some shared services, dedicated pharmaceutical waste treatment is typically the responsibility of individual tenants. This represents an additional cost burden that India's purpose-built bulk drug parks help mitigate.

FDI Framework for Pharmaceutical Manufacturing

India's FDI Policy for Pharma

India's FDI policy distinguishes between greenfield and brownfield pharmaceutical investments:

• Greenfield: 100% FDI permitted through the automatic route — no government approval needed
• Brownfield: Up to 74% FDI through the automatic route; beyond 74% requires government approval

The practical setup process for a foreign pharma manufacturer establishing a greenfield plant in India involves:

1. Incorporate a Private Limited Company via SPICe+ (2–3 weeks)
2. File FC-GPR with RBI within 30 days of FDI receipt
3. Obtain drug manufacturing license from state FDA
4. WHO-GMP certification from CDSCO (if targeting export markets)
5. Register for GST and obtain IEC for import/export
6. Environmental clearance from state Pollution Control Board

The pharmaceutical sector has received cumulative FDI inflows of INR 2,10,940 crore ($24.62 billion) from April 2000 to June 2025, demonstrating strong foreign investor confidence.

Vietnam's Pharma FDI Framework

Vietnam's regulatory reforms have significantly improved the foreign investment climate for pharma:

• The amended Law on Pharmacy (Law No. 44/2024/QH15, effective July 2025) permits foreign investors to engage in manufacturing, quality control, clinical trials, and self-distribution
• Foreign and domestic firms now receive identical treatment and procedures — a landmark departure from previous discriminatory regulations
• CIT incentives of 10–17% are available for high-tech pharma projects for up to 15 years, under Law No. 67/2025/QH15

However, Vietnam's cumulative pharmaceutical FDI of only $1.8 billion signals that foreign manufacturers are still evaluating the market rather than committing at scale.

Clinical Trials and Drug Development Infrastructure

An increasingly important factor for pharmaceutical manufacturers is access to clinical trial capabilities. India has become a significant player in global clinical research, with over 3,500 clinical trials registered annually and a network of hospitals and contract research organizations (CROs) experienced in running multicenter trials across therapeutic areas.

India's advantages for clinical research include:

• Patient diversity: Treatment-naive populations across diverse ethnic backgrounds, ideal for global registration trials
• Cost advantage: Clinical trial costs in India are estimated at 50-60% lower than in the US and EU
• Regulatory framework: CDSCO has streamlined clinical trial approvals under the New Drugs and Clinical Trials Rules (2019), with typical approval timelines of 60-90 days
• CRO ecosystem: Major global CROs (IQVIA, Covance, Parexel) operate large India centers, supplemented by capable domestic CROs like Lambda Therapeutic Research and Veeda Clinical Research

Vietnam's clinical trial infrastructure is growing, particularly for infectious disease and vaccine trials, but the overall ecosystem is smaller and less diversified. For pharmaceutical companies considering integrated manufacturing-plus-clinical development operations, India offers a more complete value chain.

Government Incentive Programs for Pharma Manufacturing

India's PLI for Pharmaceuticals

India operates two pharma-specific PLI schemes:

• PLI for Bulk Drugs: Financial outlay of INR 6,940 crore, targeting domestic production of critical APIs. Actual investment of INR 4,763 crore has been realized against INR 4,330 crore committed. The sixth application round (November 2025) focused on Meropenem and Ritonavir
• PLI for Pharmaceuticals: Covers formulations and novel drugs, with incentives of 3–10% of incremental sales

Additionally, the three bulk drug parks provide capital subsidies of up to 70% for common infrastructure and 50% for individual units within the parks.

Vietnam's Pharma Incentives

Vietnam offers broader investment incentives rather than pharma-specific programs:

• CIT exemption of 2–4 years for qualifying pharma investments, followed by 50% reduction for 4–9 years
• Import duty exemptions on manufacturing equipment and raw materials
• Land lease reductions in designated economic zones
• Circular 40/2025/TT-BYT provides procurement advantages for locally manufactured, EU-GMP certified drugs in public hospital tenders

Which Country Should You Choose?

Choose India for pharma manufacturing when:

• You are manufacturing APIs or bulk drugs (India has no peer in Asia outside China)
• You need US-FDA, EU-GMP, or WHO-GMP certification for regulated market exports
• You require access to specialized process chemists and regulatory affairs professionals
• You want to access India's $55 billion domestic pharmaceutical market
• You need PLI incentives specifically designed for pharmaceutical manufacturing

Consider a dual-country strategy when:

• You want India for API and complex formulation manufacturing while using Vietnam for finished dosage packaging targeting ASEAN distribution
• You need supply chain diversification across multiple jurisdictions
• You are a large pharma company seeking to optimize tax structures across both India's Section 115BAA rate (effective ~25.17%) and Vietnam's time-limited 10% high-tech rate

Choose Vietnam for pharma manufacturing when:

• You are focused on finished dosage form manufacturing for the ASEAN market
• You want to leverage the new Law on Pharmacy for equal treatment as domestic manufacturers
• You are producing via technology transfer and want self-distribution rights
• You want to diversify an India-centric pharmaceutical supply chain
• Your products target Vietnam's growing domestic market of $10+ billion

For comprehensive guidance on setting up pharmaceutical operations in India, explore our FDI advisory services and FEMA-RBI compliance support. For a broader comparison of manufacturing in India vs Vietnam, see our complete manufacturing comparison guide.

Key Takeaways

• India dominates API manufacturing: With 500+ APIs, 57% of WHO prequalified APIs, and $30.47 billion in annual pharma exports, India is the clear choice for any API or bulk drug manufacturing investment.
• Regulatory certifications favor India: India has 800+ US-FDA registered plants, extensive EU-GMP and WHO-GMP certified facilities, and a mature CDSCO regulatory pathway — Vietnam's certification infrastructure is still developing.
• India's talent pool is unmatched: 200,000+ pharmacy graduates annually, 10,000+ chemistry PhDs, and 3 million pharma industry workers provide a talent base Vietnam cannot match for at least a decade.
• PLI incentives drive investment: India's pharma-specific PLI with INR 6,940 crore outlay and three bulk drug parks offer incentives Vietnam does not match with sector-specific programs.
• Vietnam is best for formulations: Companies focused on finished dosage forms for the ASEAN market should consider Vietnam's reformed regulatory framework and lower entry barriers.